Indolent CD8+ Primary Cutaneous T-Cell Lymphoma of the Ear: A Case Report and Review of the Literature
LT Matthew J. Lail M.D.*1,4,LCDR Steven J. Gauerke M.D.2,4,CDR Edward F. Miles M.D3,4
1Department of Radiology, Naval Medical Center Portsmouth, USA
2Department of Pathology, Naval Medical Center Portsmouth, USA
3Division of Radiation Oncology, Department of Radiology, Naval Medical Center Portsmouth, USA
4I am a military service member. This work was prepared as part of my official duties. Title 17 U.S.C. 105 provides that ‘Copyright protection under this title is not available for any work of the United States Government.’ Title 17 U.S.C. 101 defines a United States Government work as a work prepared by a military service member or employee of the United States Government as part of that person’s official duties.
Primary cutaneous peripheral T-cell lymphoma (PTL), unspecified, is a rare, heterogeneous group of lymphomas that do not conform to any of the more well defined subcategories of cutaneous T-cell lymphoma (CTCL) as defined by the 2005 World Health Organization (WHO)-European Organization for Research and Treatment of Cancer (EORTC) classification for cutaneous lymphomas. The prognosis for these neoplasms is generally poor, although one of three provisional subtypes is characterized by an indolent clinical nature (primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoma [CSMPTCL]). There have been several case reports of what were suggested to be either a CD8+ variant of CSMPTCL or an entirely distinct subtype of CTCL, including cases with a curious predilection for the ears as well as the nose. We report a similar case of indolent CD8+ CTCL occurring on the left ear followed by a relapse on the right ear almost two years later.
Keywords: T-cell lymphoma; CD8; Ear; Indolent
CHOP :Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone;
A 43-year-old Caucasian male presented in May 1998 with a one-month history of a 1.5cm soft mass on the helix of his left ear (case 1). A punch biopsy of the skin revealed a malignant T-cell lymphoma. Staging work-up revealed no evidence of other disease except a 1cm level II lymph node on the ipsilateral side that was not pathologically enlarged. At the time he was determined to be a clinical stage IAE and he was treated with combined chemotherapy and radiotherapy. He received three cycles of chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) followed by external beam radiotherapy (EBRT) to the left upper neck and ear to a dose of 3600 cGy in 20 fractions. He completed all therapy in September 1998. He was doing well and on routine follow-upin February 2000 presented with a lesion on the right ear (case 2), which appeared similar to the original left-sided lesion. A punch biopsy again was consistent with peripheral T-cell lymphoma. He again underwent staging evaluation with no other evidence of disease. At this time it was decided to proceed with involved field radiotherapy (IFRT) alone, given limitations due to cardiotoxicity from doxorubicin. He received an additional 3600 cGy to the right ear, which was completed in April 2000. He is now 59 years old and being seen for follow-up annually, with no evidence of disease recurrence in over 14 years.
Materials and Methods
The morphology and immunohistochemical findings of case 1 and case 2 were virtually identical. Punch biopsies of the skin demonstrated extensive infiltration of the dermis by an atypical lymphoid infiltrate with sparing of the epidermis and adnexal structures. In case 1 no grenz zone was appreciated, and the sheet-like infiltrate extensively involved the deep margin with no discernible subcutaneous tissue. In case 2 a thin, clear-cut grenz zone was present and the subcutis was not involved. No necrosis, ulceration, or angiodestruction were identified. The lymphocytes were medium-sized and blast-like, with scant to moderate cytoplasm, irregular nuclear borders, open vesicular chromatin, and distinct nucleoli. Mitotic activity was brisk (1-2 figures per 40X high power field) (see Figure1). In both cases, immunohistochemical stains were strongly positive for CD3 and CD8 and negative for CD4, consistent with suppressor/ cytotoxic T-cells (see Figure 2). Additionally, the tumor cells in case 1 were positive for CD45 and CD45R0 (see Figure 3) but negative for CD4 (see Figure 4), CD20 (see Figure 5), CD30, EMA, and S-100. The tumor cells in case 2 were notable for some positivity of CD20, but they lacked expression of CD30.
Figure 1. H&E, case 1, showing extensive lymphocytic infiltration of the dermis with sparing of adnexal structures (x40). A thin grenz zone is present in case 2.
Figure 2. Immunohistochemistry demonstrating positivity for CD8, case 1 (x400).
Figure 3. Immunohistochemistry demonstrating positivity for CD45R0, case 1 (x100).
Figure 4. Immunohistochemistry demonstrating negativity for CD4, case 1 (x100).
Figure 5. Immunohistochemistry demonstrating negativity for CD20, case 1 (x100).
A number of authors over the past several years, however, have provided a foundation of case reports upon which an argument can be made for addition of either a recognized CD8+ variant of CSMPTCL or possibly an entirely separate subtype of CTCL. In 2006, Khamaysi et al  described a case of “pleomorphic CD8+ small/medium size cutaneous T-cell lymphoma” occurring on the foot, suggesting its classification as a CD8+ variant of CSMPTCL. In 2007, Petrella et al.  described four cases of an indolent, CD8+ lymphoid proliferation involving the ears and suggested that this might represent a distinct entity that had not yet been defined by WHO-EORTC classification for cutaneous lymphomas. In 2010, Beltraminelli et al.  described three cases similar to those of Petrella et al.  but emphasized that these might be more appropriately recognized as a phenotypic variant of CSMPTCL rather than a completely separate entity. Also in 2010, Ryan et al.  published yet another comparable case of a clinically indolent, CD8+ PTL, unspecified, occurring on the nose. The authors of this report remained impartial as to the best ultimate classification of these tumors and called for a collaborative review and the development of a consensus opinion on their most appropriate classification. Most recently, in 2012, Zeng et al.  reported two similar cases on the ear, contributing further to the growing body of reports of these tumors.
The clinical, morphologic, and immunohistochemical characteristics of our case are very similar to those of the cases described by the aforementioned authors. All cases involved presentation of a solitary, slowly progressive skin lesion typically found on the face, neck, or upper trunk, and with a frequent predilection for the ears. The tumor cell size was small-to-medium in all cases, and the lymphocytic infiltrate of the dermis was typically dense and diffuse. While length of follow-up has varied between these case reports, the overwhelming clinical trend has been one of indolence. Our case is somewhat unique in that the disease was bilateral with two years between the time of diagnoses, and it has one of the longest documented follow-up periods at over 16 years since initial diagnosis on the left ear and over 14 years since treatment of the right ear, with the patient doing well with no evidence of recurrence since that time.
Regardless of standpoint on the ultimate nomenclature and classification of these tumors, all of these authors have highlighted the critical importance of recognizing the clinical indolence of these lymphomas when determining the best management, whether with surgery, chemotherapy, radiotherapy, combined modalities, or simply observation. We hope that our case serves to emphasize yet again the indolent clinical nature of these tumors, as well as to provide further momentum toward and possible evidence for consideration of additions or changes in classification of these lymphomas.
Cite this article: Lail L T M J. Indolent CD8+ Primary Cutaneous T-Cell Lymphoma of the Ear: A Case Report and Review of the Literature. J J Rad Oncol. 2015, 2(1): 014.